What's Going On With Novo Nordisk Stock Monday? - Novo Nordisk (NYSE:NVO)

Novo Nordisk’s GLP-1 pill gets EU approval for cardiovascular benefits

Expanding the conditions Novo’s drugs can be prescribed for could help the Danish pharmaceutical giant spark growth as it faces pressure from Eli Lilly’s competitor drugs.

What's Going On With Novo Nordisk Stock Monday? - Novo Nordisk (NYSE:NVO)

On Monday, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) approved an update to Novo Nordisk A/S‘ (NYSE:NVO) Rybelsus (oral semaglutide) label to reflect the cardiovascular benefits seen in the SOUL trial. SOUL was a phase 3b trial carried out to evaluate the effect of Rybelsus on cardiovascular outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD) and/or chronic k…

EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits

Novo Nordisk's semaglutide gains EU approval as the first oral GLP-1 RA to reduce cardiovascular risks in type 2 diabetes patients.

Novo Nordisk secures EU approval for Rybelsus label extension

Novo Nordisk announced that the European Medicines Agency (EMA) has approved an update to the label for Rybelsus (oral semaglutide).